Immuno-Oncology: The Frontier in Caring Urological Patients

摘要

Happy New Year! Wish all readers a healthy and prosperous New Golden Mouse Year! Immunotherapy, especially immune checkpoint blockade treatment, has changed the landscape of anticancer therapy in many fields of cancer treatment. The programmed cell death-1/programmed cell death-ligand 1 blockade alone has resulted in better treatment outcomes than conventional therapies, such as chemotherapy and targeted therapy in advanced urothelial carcinoma and renal cell carcinoma (RCC). In this issue, Guo JC and Lin CC presented "Rational combination with an immunotherapy backbone in genitourinary cancers." This is a must read for all urologists, particularly for those under training. Hsueh FJ and Tsai YC summarized the "current and future aspect of immunotherapy for advanced renal cell carcinoma." Through this article, one may learn how to use immunotherapy in advanced RCC and keep in pace with the development of immuno-oncology in genitourinary cancers.